Themis Medicare gets approval for immunomodulatory antiviral drug ‘VIRALEX’

04 Mar 2022 Evaluate

Themis Medicare has received approval for its immunomodulatory antiviral drug VIRALEX (Generic name: Inosine Pranobex) for treatment of COVID-19, from Drug Controller General of India (DCGI).

The drug regulatory authority granted permission to manufacture and market this new drug for restricted emergency use as add on therapy for treatment of mild and moderate COVID-19, under NDCT Rules 2019 based on evaluation in consultation with the Subject Expert Committee (SEC) as part of accelerated approval process considering the emergency situation and unmet medical need in light of COVID-19 outbreak in the country. VIRALEX would be available on prescription.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

263.10 0.75 (0.29%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.